NASDAQ:IRMD - Iradimed Stock Price, News, & Analysis

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

Iradimed Corp (NASDAQ:IRMD) posted its quarterly earnings results on Tuesday, April, 30th. The medical equipment provider reported $0.11 EPS for the quarter, hitting the consensus estimate of $0.11. The medical equipment provider earned $8.44 million during the quarter, compared to analysts' expectations of $8.38 million. Iradimed had a net margin of 23.00% and a return on equity of 13.98%. View Iradimed's Earnings History.

Iradimed is scheduled to release their next quarterly earnings announcement on Tuesday, July 30th 2019. View Earnings Estimates for Iradimed.

Iradimed issued an update on its second quarter 2019 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of $0.14-0.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.17. The company issued revenue guidance of $8.8-9 million, compared to the consensus revenue estimate of $9.39 million.Iradimed also updated its FY 2019 guidance to $0.69-0.73 EPS.

1 brokerages have issued 1 year price targets for Iradimed's shares. Their predictions range from $35.00 to $35.00. On average, they expect Iradimed's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 74.9% from the stock's current price. View Analyst Price Targets for Iradimed.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.

News headlines about IRMD stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iradimed earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the next few days. View News Stories for Iradimed.

Some companies that are related to Iradimed include Intersect ENT (XENT), AngioDynamics (ANGO), Cerus (CERS), Orthopediatrics (KIDS), Anika Therapeutics (ANIK), SurModics (SRDX), MiMedx Group (MDXG), OraSure Technologies (OSUR), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), SI-Bone (SIBN), GenMark Diagnostics (GNMK), Vapotherm (VAPO), Accuray (ARAY) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), BioTelemetry (BEAT), Intuitive Surgical (ISRG), Paypal (PYPL), Palo Alto Networks (PANW), Alphabet (GOOG), IntriCon (IIN), Micron Technology (MU), GrubHub (GRUB) and ABIOMED (ABMD).

Iradimed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.10%), BlackRock Inc. (3.06%), Cadence Capital Management LLC (1.17%), RK Capital Management LLC (1.16%), Spark Investment Management LLC (0.50%) and Fiera Capital Corp (0.46%). Company insiders that own Iradimed stock include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.

IRMD stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Timpani Capital Management LLC, Morgan Stanley, O Shaughnessy Asset Management LLC and Federated Investors Inc. PA. Company insiders that have sold Iradimed company stock in the last year include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.

IRMD stock was purchased by a variety of institutional investors in the last quarter, including RK Capital Management LLC, Fiera Capital Corp, Cadence Capital Management LLC, Spark Investment Management LLC, Renaissance Technologies LLC, BlackRock Inc., Marshall Wace LLP and Marshall Wace LLP. View Insider Buying and Selling for Iradimed.

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IRMD stock can currently be purchased for approximately $20.01.

Iradimed has a market capitalization of $223.31 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 95 workers across the globe.View Additional Information About Iradimed.

The official website for Iradimed is http://www.iradimed.com/.

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]